Busch Matthew C., an insider at Amgen Inc (AMGN), sold 4,414 shares of the company on November 4, 2025, at a price of $296.70 per share, totaling $1.31 million. Following this transaction, he retains 4,414 shares of the biotechnology firm.
Amgen, headquartered in Thousand Oaks, California, focuses on the discovery, development, manufacture, and marketing of human therapeutics. The company, which employs approximately 28,000 individuals, has a market capitalization of $169.9 billion and a price-to-earnings ratio (P/E) of 24.26. Its diverse portfolio includes products such as EPOGEN, Neulasta, and Repatha.
Insider transactions like this one are reported to the SEC, providing transparency into executives' views on their company's stock. While such sales can occur for various reasons—including diversification or personal financial needs—they should not be viewed in isolation. Investors are encouraged to consider patterns of insider activity over time and across multiple executives when evaluating these signals.
Amgen's upcoming earnings report is scheduled for April 28, 2026, with an estimated earnings per share (EPS) of $5.15 and projected revenue of $8.8 billion.